COMPOSITION
Each vial of 1 mg contains :
Vincristine Sulphate (anhydrous) B.P.
1 mg.
Lactose B.P.
q.s
Each vial of 2mg contains :
Vincristine Sulphate (anhydrous) B.P.
2 mg.
Lactose B.P.
q.s
Each vial of 5mg contains :
Vincristine Sulphate (anhydrous) B.P. 5mg.
Lactose B.P.
q.s
PREPARATION OF SOLUTION
Dissolve contents of the 1 mg, 2 mg and 5 mg vials in 10
ml Sodium Chloride Injection B.P.
STORAGE
Store in a refrigerator between 2° to 8° C.
PRESENTATION
Vial containing 1 mg plus diluent
Vial containing 2 mg plus diluent
Vial containing 5 mg
ACTIONS
It inhibits microtubule formation in the mitotic spindle
resulting in an arrest of dividing cells at the metaphase
stage.
INDICATIONS
Vincristine Sulphate is indicated in acute leukemia. Also
useful in combination with other oncolytic agents in Hodgkin's
disease, non-Hodgkin's malignant lymphomas (lymphocytic,
mixed-cell histolytic, undifferentiated, nodular, and diffuse
types), rhabdomyosarcoma, neuroblastoma and Wilms tumor.
CONTRAINDICATIONS
Contraindicated in patients with the demyelinating form
of Charcot-Marie-Tooth syndrome.
PREGNANCY
The drug can cause fetal harm administered to a pregnant
woman.
DRUG INTERACTIONS
Combination chemotherapy (including Vincristine Sulphate)
may decrease plasma levels of digoxin and phenytoin.
ADVERSE REACTIONS
In general, adverse reactions are reversible and are related
to dosage. Most common is hair loss. Hypersensitivity, gastrointestinal
toxicity, genitourinary toxicity, cardiovascular toxicity,
neuromuscular side effects, endocrine toxicity, hematologic
toxicity etc. are reported.
OVERDOSAGE
In children under 13 years of age, death has occurred following
doses of the drug that were 10 times those recommended for
therapy. Adults can experience severe symptoms after single
doses of 3 mg / m2 or more. Supportive care should
include prevention of side effects resulting from the syndrome
of inappropriate antidiuretic hormone secretion, administration
of anticonvulsant, monitoring the cardiovascular system.
DOSAGE AND ADMINISTRATION
Administer IV only, at weekly intervals. Inject solution
either directly into a vein or into the tubing of a running
IV infusion . Injection may be completed in about 1 minute.
For adults 1.4 mg to1.5 mg / m2 upto a maximum
weekly dose of 2 mg / m2.
For children 2 mg / m2. For children weighing
less than 10 kg or less or having a body surface area less
than 1 m2 give 0.05 mg / kg once a week. In hepatic
function impairment a 50% reduction in the dose is recommended
for patients having a direct serum bilirubin value >
3 mg / dl.
